BEAT BioTherapeutics Corp. (BEATBio) is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. Heart failure constitutes a large and growing epidemic. The World Health Organization reports that 29% of deaths worldwide are due to cardiovascular disease. Approximately 6 million Americans are living with heart failure today. New therapies to address this epidemic are urgently needed to decrease patient mortality, improve patient quality of life and address the burgeoning cost of care.